转移灶导向治疗延长寡进展去势抵抗性前列腺癌系统治疗疗效并改善临床结局
该回顾性研究评估立体定向消融放疗(SABR)对寡进展去势抵抗性前列腺癌(CRPC)的疗效。68例患者接受MDT后中位PSA失败时间9.7个月,TTNI 15.6个月,DMFS 10.8个月。与仅更换系统治疗相比,MDT与更长的TTNI和DMFS相关,多因素分析仍保持关联。
要点
- MDT后中位PSA失败时间9.7个月,TTNI 15.6个月,DMFS 10.8个月
- 12和24个月局部失败累积发生率分别为2.1%和13.8%
- 与仅更换系统治疗相比,MDT改善TTNI和DMFS,多因素分析仍显著
核心结论
- 在寡进展CRPC回顾性队列中,MDT与有利结局相关,相比仅更换系统治疗改善肿瘤控制。
- 未来需前瞻性试验确认这些发现。
研究设计与样本
- 回顾性评估寡进展CRPC患者,报告MDT后结局,并与仅更换系统治疗的患者比较。
- 共纳入68例患者,其中MDT组31例,仅更换系统治疗组52例。
- 干预为对寡进展病灶行立体定向消融放疗(SABR)。
主要发现
- MDT后中位PSA复发时间9.7个月,TTNI 15.6个月,DMFS 10.8个月。
- 共治疗112个病灶,12和24个月局部失败累积发生率分别为2.1%和13.8%。
- 单因素分析中局部复发风险相关因素为年龄(HR 1.07,p=0.03)和Gleason分级分组(HR 2.20,p=0.07)。
- 与仅更换系统治疗相比,MDT组中位PSA失败时间9.7 vs 4.2个月(p=0.066),TTNI 14.9 vs 8.8个月(p=0.025),DMFS 12.7 vs 8.9个月(p=0.045)。
- 多因素分析中MDT仍与改善结局相关。
临床怎么用
- 对于寡进展CRPC患者,可考虑对进展病灶行SABR以延长系统治疗疗效和改善临床结局。
- 需前瞻性试验确定放疗在转移性CRPC中的最佳整合方式。
局限性
- 回顾性研究设计。
- 样本量有限(68例)。
- 需要前瞻性试验验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Available therapies for castrate-resistant prostate cancer (CRPC) confer minimal survival advantage; thus, there is interest in metastasis-directed therapy (MDT) for oligometastatic or oligoprogressive disease to improve outcomes. Here, we describe outcomes of oligoprogressive CRPC treated with stereotactic ablative radiotherapy (SABR). OBJECTIVE: To report outcomes of oligoprogressive CRPC treated with MDT using SABR. DESIGN, SETTING, AND PARTICIPANTS: Patients with oligoprogressive CRPC were retrospectively evaluated, and outcomes following MDT were reported. Outcomes were additionally compared with oligoprogressive CRPC treated with change in systemic therapy alone. INTERVENTION: SABR to oligoprogressive lesions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes of interest were time to prostate-specific antigen (PSA) failure, time to next intervention (TTNI), distant metastasis-free survival (DMFS), and overall survival. Survival analysis was performed using the Kaplan-Meier method, and univariable analysis and multivariable analysis (MVA) were performed. RESULTS AND LIMITATIONS: A total of 68 patients were included. After MDT, median time to PSA recurrence, TTNI, and DMFS were 9.7, 15.6, and 10.8 months, respectively. A total of 112 lesions were treated, and the cumulative incidences of local failure at 12 and 24 months were 2.1% and 13.8%, respectively. Factors associated with the risk of local recurrence on univariable analysis were age (hazard ratio [HR] 1.07, p = 0.03) and Gleason grade group (HR 2.20, p = 0.07). Compared with change in systemic therapy alone (n = 52), MDT (n = 31) was associated with improved median time to PSA failure (9.7 vs 4.2 months, p = 0.066)), TTNI (14.9 vs 8.8 months, p = 0.025), and DMFS (12.7 vs 8.9 months, p = 0.045), and remained associated with improved outcomes on MVA. CONCLUSIONS: In a retrospective cohort of oligoprogressive CRPC patients, MDT was associated with favorable outcomes and improved cancer control as compared with change in systemic treatment alone. Future prospective trials are needed to confirm these findings. PATIENT SUMMARY: In this report, we retrospectively analyzed outcomes of patients with oligoprogressive castrate-resistant prostate cancer treated with radiation therapy to progressing lesions. Our results suggest that treatment of these lesions with radiation therapy can result in sustained periods of disease-free survival and might add benefit in addition to systemic therapy at the time of progression. These results need to be verified in a prospective trial to identify the optimal integration of radiation therapy into metastatic castrate-resistant prostate cancer.
引用
- Deek MP, Taparra K, Phillips R, et al. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. Eur Urol Oncol. 2020. PMID: 32536574. doi:10.1016/j.euo.2020.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。